{
  "ticker": "MAP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967402",
  "id": "02967402",
  "pages": 42,
  "price_sensitive": false,
  "date": "20250708",
  "time": "1604",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06lltcwlnmm05s.pdf",
  "summary": "### **Capital Raising Announcement Summary**  \n\n#### **Key Details:**  \n- **Structure:** Capital raising comprising:  \n  - **Placement:** $12.5M (AUD) via 138,888,889 new shares at $0.09/share (split into Tranche 1 and Tranche 2).  \n  - **Share Purchase Plan (SPP):** $2.0M (AUD) underwritten, offered to eligible shareholders at $0.09/share.  \n  - **Options:** Each Placement/SPP participant receives **1 free option for every 2 shares subscribed**, exercisable at $0.14 expiring in 2 years.  \n  - **Sonic Option:** 1 option issued to Sonic Healthcare (exercisable into up to 46.3M shares + 11.6M attaching options).  \n\n#### **Timetable:**  \n- **General Meeting:** 8 August 2025 (to approve Tranche 2, options, and Sonic Option).  \n- **Expected issue date for Tranche 2/SPP/Sonic Option:** 13 August 2025.  \n\n#### **Use of Funds ($14.5M total):**  \n- Expand commercialization of microbiome tests (*MetaXplore*, *MetaPanel*) in AU/UK.  \n- Strengthen sales, marketing, and clinical evidence.  \n- Working capital and offer costs.  \n\n#### **Capital Structure Impact (Undiluted):**  \n- **Current:** 447.9M shares, 26.8M options.  \n- **Post-Raising (undiluted):** 609.0M shares, 107.4M options.  \n- **Fully Diluted:** 774.2M shares (if all options exercised).  \n\n#### **Related Party Participation:**  \n- Directors Pasquale Rombola (600k Tranche 2 shares + 300k options) and Ian Frazer (833k shares + 417k options) require shareholder approval (Resolutions 4\u20135).  \n\n### **Material Takeaways for Trading/Capital Markets:**  \n1. **Equity Dilution:** ~36% increase in shares outstanding (undiluted).  \n2. **Options Overhang:** Potential future dilution from 107M+ options.  \n3. **Strategic Alignment:** Sonic Healthcare\u2019s participation signals continued partnership.  \n4. **Liquidity Impact:** Post-raise cash balance supports near-term operations (~$14.5M gross).  \n\n*Omitted:* Routine procedural details, director nominations, and non-material operational updates.  \n\n**Actionable Info:** Monitor GM approval (8 Aug) and post-issue capital structure (from 13 Aug).",
  "usage": {
    "prompt_tokens": 28920,
    "completion_tokens": 558,
    "total_tokens": 29478,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T06:22:10.860108"
}